Posted by Michael Wonder on 29 Jul 2026
Haya Therapeutics receives FDA fast track designation for HTX-001
28 July 2026 - Haya Therapeutics announced that the US FDA has granted fast track designation for HTX-001 for the treatment of symptomatic non-obstructive hypertrophic cardiomyopathy.
The first in class investigational long non-coding RNA targeting therapy is in a Phase 1a/b trial, with the first cohort dosed this past May.
